TBTerry W. Bilverstone

Terry W. Bilverstone

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Terry W. Bilverstone has a total of 26 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Complete genome sequence of Clostridioides difficile NCTC 12727, a PCR ribotype 001 reference strain

    by Samiksha Venkatesan, Michael Macey, Uzaira Saniah, Ernesto Abel-Santos, Rachel McMullan, Ilias Kounatidis, Terry Bilverstone

    We report the complete genome sequence of the PCR ribotype 001 Clostridioides difficile strain NCTC 12727 obtained by hybrid genome assembly, manual curation, and PCR validation. The circular 4,371,963 bp genome (28.99% GC) contained two multi-copy mobile genetic elements encompassing a prophage and a Tn 916 -like element, respectively.

  • Open Access

    Post-Synthesis Modulation of the Physicochemical Properties of Green-Synthesized Iron Oxide Nanoparticles with Tween 80 to Enhance Their Antibacterial Activity and Biocompatibility

    by Marwa R. Bakkar, Alaa M. Ali, Gehad E. Elkhouly, Nermeen R. Raya, Terry W. Bilverstone, Nicholas P. Chatterton, Gary R. McLean, Yasmin Abo-Zeid

    Background: Iron oxide nanoparticles (IONPs) have broad-spectrum antimicrobial activity, with negligible potential for resistance development, excellent biocompatibility, and therefore, could be promising alternatives to conventional antimicrobials. However, their industrial-scale production relies on chemical synthesis that involves toxic reagents, imposing potential environmental hazards. In contrast, green synthesis offers an eco-friendly alternative, but our previous study found that green-synthesized IONPs (IONPs-G) exhibited a lower antibacterial activity and a higher cytotoxicity compared to chemically synthesized counterparts, likely due to nanoparticle aggregation. Objectives: To address this challenge, the current study presents a simple, effective, economic, scalable, and eco-friendly strategy to optimize the physicochemical properties of IONPs-G post-production without requiring extensive modifications to synthesis parameters. Methods: IONPs-G were dispersed in a solvent mixture containing Tween 80 (Tw80). Subsequently, in vitro antimicrobial and in vivo cytotoxicity studies on rabbits’ skin and eye were conducted. Results: The formed nanoparticles’ dispersion (IONPs-GTw80) had a particle size of 9.7 ± 2.1 nm, a polydispersity index of 0.111 ± 0.02, and a zeta potential of −11.4 ± 2.4 mV. MIC of IONPs-GTw80 values against S. aureus and E. coli were reduced by more than ten-fold compared to IONPs-G. MBC was twice MIC, confirming the bactericidal activity of IONPs-GTw80. In vivo studies of IONPs-GTw80 confirmed their biocompatibility with intact/abraded skin and eyes; this was further confirmed by histopathological and biochemical analyses. Conclusions: IONPs-GTw80 might be recommended as a disinfectant in healthcare settings or a topical antimicrobial agent for treatment of infected wounds. Nevertheless, further studies are required for their clinical translation.


  • Open Access

    Deletion of rgaS reduces virulence in a mouse model of Clostridioides difficile infection

    by Terry W. Bilverstone, Morgan E. Simpson, Nicholas Hagspiel, William A. Petri, Sarah A. Kuehne, Nigel P. Minton

  • Open Access

    Allelic exchange technologies for Clostridioides difficile research and their application in toxin studies

    by Terry W Bilverstone

    The ability to precisely manipulate the genome of Clostridioides difficile allows for the generation of mutants that can be characterized to unveil critical aspects relating to pathogenesis and virulence. Such findings can ultimately direct the development of antivirulence agents to combat C. difficile infection, by small molecule inhibition. In this review, the mechanisms underpinning the most widely adopted allelic exchange technologies for generating precise genomic mutations in C. difficile, are discussed. The advantages and disadvantages of each system are considered. In addition, a comprehensive review of the application of these tools for the study of C. difficile toxins and genes residing within the toxin loci, is presented.

  • Open Access

    A tale of two phage tails: Engineering the host range of bacteriophages infecting Clostridioides difficile

    by Joanna P. Steczynska, Sarah J. Kerr, Michelle L. Kelly, Michaella J. Whittle, Terry W. Bilverstone, Nigel P. Minton

    Clostridioides difficile infection (CDI) is a leading cause of antibiotic-associated diarrhoea across the globe. Although treatable with a restricted number of antibiotics, the emergence of resistant variants and high relapse rates necessitate alternative countermeasures. Phage therapy represents an attractive option. However, its implementation is handicapped by the narrow host specificity of the C. difficile bacteriophages isolated to date. One strategy to rationally expand phage host range would be to make appropriate modifications to the phage receptor binding protein (RBP). Here, we identify the tail fibre as the RBP of two Myoviridae phages, ΦCD1801 and ΦCD2301, which were previously isolated and propagated using the C. difficile strains CD1801 (RT078) and CD2301 (RT014), respectively. Contrary to studies into reprogramming the host ranges of phage of other bacterial other species, exchanging the tail fibre genes ( tcf/tfp ) alone between the two phage was insufficient to change host specificity. Rather, alterations to host range were dependent their exchange together with a putative chaperone encoded by hyp , localised adjacent to the tail fibre gene. Capitalising on this discovery, CRISPR/Cas9 was used to change the host range of one phage to that of the other by swapping the respective tcf/tfp and hyp genes. Significantly, one of the resulting mutants, surpassed both parental phages in terms of host range and efficiency of infection. This is the first time that genome engineering has successfully expanded the host range of a C. difficile phage, a prerequisite for implementing phage for the treatment of CDI. Importance: Alternatives to antibiotics for treating Clostridioides difficile infection (CDI) are urgently required. Phage therapy presents an attractive option as it has the potential to clear the infection with minimal microbiome disruption and eliminate the possibility of recurrence. However, the C. difficile bacteriophages isolated to date have highly restricted host ranges. Moreover, rational strategies to alter specificity have till now been precluded as the identity of the phage receptor binding proteins involved was largely unknown. Here, we demonstrated that tail fibre proteins and an associated putative chaperone determine the host range of two Myoviridae phage. This enabled the alteration of specificity through CRISPR-mediated genome editing and the creation of a phage derivative with a host range and infection efficiency exceeding that of the parental phages. This is the first time that the host range of a C. difficile phage has been successfully expanded through rational genome engineering.


  • Open Access

    What's a SNP between friends: The lineage of Clostridioides difficile R20291 can effect research outcomes

    by Jorge Monteford, Terry W. Bilverstone, Patrick Ingle, Sheryl Philip, Sarah A. Kuehne, Nigel P. Minton